P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
Natalie Galanina,Rafael Bejar,Michael Y. Choi,Aaron M. Goodman,Matthew J. Wieduwilt,Carolyn Mulroney,Lisa Kim,Huwate Yeerna,Pablo Tamayo,Jo-Anne Vergilio,Tariq I. Mughal,Tariq I. Mughal,Vincent A. Miller,Catriona Jamieson,Razelle Kurzrock +14 more
TL;DR: Most patients with hematologic malignancies have adequate tissue for comprehensive genomic profiling, and 75% had alterations that may be pharmacologically tractable with gene- or immune-targeted agents.
Journal ArticleDOI
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Kris C. Wood,David J. Konieczkowski,David J. Konieczkowski,Cory M. Johannessen,Cory M. Johannessen,Jesse S. Boehm,Pablo Tamayo,Olga B Botvinnik,Jill P. Mesirov,William C. Hahn,William C. Hahn,David E. Root,Levi A. Garraway,Levi A. Garraway,David M. Sabatini +14 more
TL;DR: The MicroSCALE platform described here may enable new classes of large-scale, resource-efficient screens that were not previously feasible, including those involving combinations of cell lines, perturbations, and assay outputs or those involving limited numbers of cells and limited or expensive reagents.
Journal ArticleDOI
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
Jong Wook Kim,Jong Wook Kim,Jong Wook Kim,Omar O. Abudayyeh,Huwate Yeerna,Chen-Hsiang Yeang,Chen-Hsiang Yeang,Michelle Stewart,Russell W. Jenkins,Shunsuke Kitajima,David J. Konieczkowski,David J. Konieczkowski,Kate Medetgul-Ernar,Taylor B. Cavazos,Clarence K. Mah,Stephanie Ting,Eliezer M. Van Allen,Eliezer M. Van Allen,Ofir Cohen,Ofir Cohen,John H McDermott,Emily Damato,Andrew J. Aguirre,Andrew J. Aguirre,Andrew J. Aguirre,Jonathan Liang,Arthur Liberzon,Gabriella Alexe,John G. Doench,Mahmoud Ghandi,Francisca Vazquez,Francisca Vazquez,Barbara A. Weir,Aviad Tsherniak,Aravind Subramanian,Karina Meneses-Cime,Jason Park,Paul A. Clemons,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,David Thomas,Jesse S. Boehm,David A. Barbie,David A. Barbie,William C. Hahn,Jill P. Mesirov,Jill P. Mesirov,Pablo Tamayo,Pablo Tamayo +49 more
TL;DR: The results show that the Onco-GPS is an effective approach to explore the complex landscape of oncogenic cellular states across cancers, and an analytic framework to summarize knowledge, establish relationships, and generate more effective disease models for research or as part of individualized precision medicine paradigms.
Journal ArticleDOI
Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Chao Liu,Chao Liu,Sayed Sadat,Koji Ebisumoto,Akihiro Sakai,Bharat A. Panuganti,Shuling Ren,Shuling Ren,Yusuke Goto,Sunny Haft,Takahito Fukusumi,Mizuo Ando,Yuki Saito,Theresa Guo,Pablo Tamayo,Huwate Yeerna,William Kim,Jacqueline A. Hubbard,Andrew B. Sharabi,J. Silvio Gutkind,Joseph A. Califano +20 more
TL;DR: Cannabinoids can promote progression of HPV-positive HNSCC through p38 MAPK pathway activation as well as nonselective cannabinoid receptor activation in cell lines and animal models.
Journal ArticleDOI
HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.
Shuling Ren,Shuling Ren,Daria A. Gaykalova,Theresa Guo,Alexander V. Favorov,Alexander V. Favorov,Elana J. Fertig,Pablo Tamayo,Juan Luis Callejas-Valera,Juan Luis Callejas-Valera,Mike Allevato,Mara Gilardi,Jessica Santos,Takahito Fukusumi,Akihiro Sakai,Mizuo Ando,Sayed Sadat,Chao Liu,Guorong Xu,Kathleen M. Fisch,Zhiyong Wang,Alfredo A. Molinolo,J. Silvio Gutkind,Trey Ideker,Wayne M. Koch,Joseph A. Califano +25 more
TL;DR: Models of the E2/E4/E5 carcinogenesis show p53 dependent enhanced proliferation in vitro, as well as increased susceptibility to induction of cancer in vivo, and this subtype is susceptible to combination FGFR and mTOR inhibition, with implications for targeted therapy.